newsfilter
← Latest News
ACCESS Newswire·

Novamind Reports FY2021 Financial Results and Operating Highlights

Industry-leading revenue, $6,069,247 in FY2021 Total working capital of $9,680,431 to fund operations­­ Expanded network to six clinics and three clinical research sites Contracted for eight clinical trials Granted DEA Schedule 1 licenses for psil